The rise of bioprinted tissue holds immense promise for groundbreaking advancements in regenerative medicine, drug testing, and disease modeling. As bioprinting technology continues to evolve, it has unlocked the potential to create complex tissue structures with well-defined biological functionalities. Comprehensive assessment of bioprinted tissues is critical to ensure their quality, functionality, and safety for both research and clinical applications. At RPI, we have developed specialized optical imaging platforms to enable molecular, structural, and mechanical image-driven assessments of large tissue constructs. These platforms are instrumental in evaluating tumor organoid manufacturing and their responses to drug exposure.

Lead PI: Dr. Xavier Intes